Rockefeller Capital Management L.P. Tg Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.48 - $35.0 $402,727 - $910,560	-26,016 Reduced 99.92%	21 $0
Q1 2023 May 17, 2023	BUY	$10.23 - $19.34 $255,750 - $483,500	25,000 Added 2410.8%	26,037 $391,000
Q4 2022 Mar 06, 2023	BUY	$5.01 - $11.83 $3,507 - $8,281	700 Added 207.72%	1,037 $12,000
Q3 2022 Nov 02, 2022	BUY	$4.57 - $8.4 $95 - $176	21 Added 6.65%	337 $1,000
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $7 - $20	-1 Reduced 0.32%	316 $3,000
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $30,141 - $70,416	-1,983 Reduced 86.22%	317 $6,000
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $980 - $1,820	-45 Reduced 1.92%	2,300 $76,000
Q2 2021 Aug 10, 2021	BUY	$32.5 - $48.96 $1,462 - $2,203	45 Added 1.96%	2,345 $90,000
Q1 2021 May 11, 2021	BUY	$41.61 - $54.3 $41,610 - $54,300	1,000 Added 76.92%	2,300 $110,000
Q4 2020 Feb 12, 2021	BUY	$25.27 - $54.9 $7,581 - $16,470	300 Added 30.0%	1,300 $67,000
Q3 2020 Nov 13, 2020	BUY	$18.49 - $27.24 $18,490 - $27,240	1,000 New	1,000 $26,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.